Tofacitinib may induce hair regrowth in over 80 percent children with alopecia: Study
Australia: Oral tofacitinib may be an effective and well-tolerated treatment strategy for in some children with alopecia areata (AA), suggests a recent study in the journal Pediatric Dermatology.
Tofacitinib, a selective 1/3 janus kinase inhibitor (JAKi), is used for the treatment of inflammatory diseases including alopecia areata, vitiligo, sarcoidosis, systemic lupus, atopic dermatitis, psoriasis, rheumatoid arthritis, and psoriatic arthritis. Alopecia areata is an autoimmune hair loss condition that affects people across all age groups. Prolonged disease duration and early age of onset is linked to poor prognosis. Phase 3 trials are investigating the role of janus kinase inhibitors in adults and adolescents with AA.
Rebekka Jerjen, Sinclair Dermatology, Melbourne, VIC, Australia, and colleagues evaluated the use of oral tofacitinib in pre‐adolescent patients with AA.
For the purpose, they performed a retrospective review of case records of all pre‐adolescent patients having AA and treated with oral tofacitinib in a single center between 2018 and 2019. 14 patients aged 7 to 11 years were identified.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.